These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32663057)

  • 1. Efficacy of immune checkpoint inhibitors in different types of melanoma.
    Rossi E; Schinzari G; Maiorano BA; Indellicati G; Di Stefani A; Pagliara MM; Fragomeni SM; De Luca EV; Sammarco MG; Garganese G; Galli J; Blasi MA; Paludetti G; Scambia G; Peris K; Tortora G
    Hum Vaccin Immunother; 2021 Jan; 17(1):4-13. PubMed ID: 32663057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.
    Wierenga APA; Cao J; Luyten GPM; Jager MJ
    Int Ophthalmol Clin; 2019; 59(2):53-63. PubMed ID: 30908279
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy for advanced melanoma: current situation in Japan.
    Kato J; Uhara H
    Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
    Masaoutis C; Kokkali S; Theocharis S
    Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma.
    Lu JE; Chang JR; Berry JL; In GK; Zhang-Nunes S
    Int Ophthalmol Clin; 2020; 60(2):77-89. PubMed ID: 32205655
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune thrombocytopenic purpura caused by immune checkpoint inhibitors for uveal malignant melanoma.
    Takemoto K; Makino T; Kagoyama K; Furukawa F; Mizawa M; Shimizu T
    J Dermatol; 2023 Sep; 50(9):e292-e294. PubMed ID: 37017454
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel Approaches to the Systemic Management of Uveal Melanoma.
    Khan S; Carvajal RD
    Curr Oncol Rep; 2020 Jul; 22(10):104. PubMed ID: 32725406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
    Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
    BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
    Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C
    Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.
    Errington JA; Conway RM; Walsh-Conway N; Browning J; Freyer C; Cebon J; Madigan MC
    Br J Ophthalmol; 2012 Mar; 96(3):451-8. PubMed ID: 22190731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
    Jindal V
    Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
    Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
    Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
    Finger PT; Pavlick AC
    J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjunctival Melanoma: Current Treatments and Future Options.
    Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
    Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review.
    Alhammad FA; Alburayk KB; Albadri KS; Butt SA; Azam F
    Orbit; 2024 Feb; 43(1):49-57. PubMed ID: 37052129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas.
    Hoyek S; Kourie HR; Labaki C; Antoun J
    Immunotherapy; 2020 Nov; 12(16):1149-1152. PubMed ID: 33076742
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.